With revenue up 13%, gross margins at 77%, and half the trial enrolled, AtriCure is executing on both financial and clinical fronts.
ATRC · Earnings Call · 2026-07-23
The second quarter of 2026 marked a clear inflection point for AtriCure. Revenue growth stayed in double digits, profitability surged, and the company's flagship clinical trial hit a major enrollment milestone. The story is no longer just about product adoption – it's about an operating model that is scaling, and a pipeline of evidence that could redefine how cardiac surgeons treat atrial fibrillation.
The Profitability Inflection
AtriCure's top line grew 12.8% reported (12.4% constant currency) to $153.6 million, with U.S. revenue up 13.6%. More importantly, the bottom line flexed: adjusted EBITDA reached $27.3 million, up 78% year-over-year, and the company recorded net income of $9.0 million, a swing of over $15 million from the prior-year loss. The improvement was driven by a 270 basis point expansion in gross margin to 77.2%, aided by favorable product mix – particularly the adoption of higher-margin new products like cryoSPHERE MAX and the AtriClip Mini devices – and manufacturing efficiencies.
CFO Angie Wirick encapsulated the quarter's financial performance:
Our team drove a strong second quarter adjusted EBITDA result of $27.3 million compared to $15.4 million for the second quarter of 2025, a 78% increase year-over-year.
The company raised its full-year adjusted EBITDA guidance to $85–$89 million, implying a ~14% margin at the midpoint, and reiterated plans for positive cash generation. This is a marked shift from the company's historical cash-burn profile. As Mike Carrel noted, “We also generated over $27 million of adjusted EBITDA and $9 million of net income, further reinforcing the outstanding progress we are making to improve profitability and demonstrate the overall strength of our business.” — Michael H. Carrel, President and CEO · 2026-07-23 Indeed, the revenue trajectory shows a company that has more than tripled quarterly sales since 2016, while steadily improving margins.
Pain Management: The Growth Engine
The pain management franchise continues to be the standout growth driver. Worldwide pain management revenue grew 27% in Q2, with U.S. sales up 27.8% to $27.1 million. The adoption of cryoSPHERE MAX, which now represents roughly 75% of U.S. pain management revenue, is expanding into new therapeutic areas. CEO Mike Carrel highlighted early success at major cancer centers: “We recently completed evaluations of cryoSPHERE MAX at 2 major cancer centers in the United States with positive outcomes and continue to expand our field team to support this growth.” — Michael H. Carrel, President and CEO · 2026-07-23
The pipeline is deepening. The cryoXT probe, designed for below-knee amputations, is in its early commercial phase, with presentations at vascular surgery meetings generating excitement. “Surgeons and care teams see a difference with cryoXT in the patient experience and an improvement in the recovery from their surgeries” — Michael H. Carrel, President and CEO · 2026-07-23, Carrel observed. The company is still in the early innings of this market, but the Cryo Nerve Block platform has multiple applications beyond thoracic surgery – sternotomy and amputation are just the beginning.
This momentum was building even a year ago. In the Q1 2026 call, CFO Angie Wirick reported “10% growth in the cryoSPHERE MAX accounts within the quarter” — Angela Wirick, CFO · 2026-05-06. That growth has compounded, with the company now adding accounts at a robust pace while also increasing utilization at existing accounts.
Clinical Catalysts and Competitive Moat
The most strategically significant development this quarter is the progress of the BoxX NoAF trial. Enrollment has surpassed 500 patients, exceeding 50% of the 960-patient target, with full enrollment expected by year-end. This trial - studying the benefits of ablation and left atrial appendage management in cardiac surgery patients without pre-existing atrial fibrillation - could expand the company's addressable market significantly. Data readouts are expected in the first half of 2027, and management believes the trial's randomized design and PMA pathway will be a powerful differentiator.
The LeAAPS trial, examining stroke reduction in >6,500 patients, continues follow-up. These trials, combined with the company's existing clinical compendium, form a formidable moat against new entrants in the appendage management market.
In the open ablation franchise, growth of 11% was driven by the EnCompass clamp. The upcoming STS quality metric, which will mandate treatment of concomitant Afib, is a major catalyst. As Mike Carrel has repeatedly noted, “We are still severely underpenetrated in the CABG market” — Michael H. Carrel, Chief Executive Officer · 2025-10-29. The quality metric is designed to change that, potentially lifting ablation rates from ~35% to >80% over time.
Competition from Medtronic and potentially Edwards is a concern for investors, but AtriCure's response is anchored in product superiority, clinical evidence, and a 500+ person field force. The company's commitment to innovation is evident in its next-generation AtriClip devices and the upcoming PFA-equipped EnCompass clamp, which is on track for first-in-human in Europe and an IDE submission later this year.
With the stock up ~73% over the past 90 days, the market is rewarding this execution. The combination of accelerating profitability, a robust pain management franchise, and a clinical pipeline that could triple the cardiac surgery opportunity makes AtriCure a name to watch.